November 8, 2026
An AI Conversation
Yes, hematopoietic stem cells (HSCs) can differentiate into cancer tumor cell phenotypes, particularly in the context of blood malignancies and potentially within solid tumor microenvironments.
- Blood Malignancies: In diseases like acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL), the cell of origin is often an HSC. A primary mutation occurs at the HSC level, creating a pre-leukemic HSC that retains multipotent differentiation but acquires self-renewal properties, eventually generating leukemia stem cells (LSCs) and malignant blood cells.[1]
- Solid Tumors: Evidence suggests that cancer stem cells (CSCs) in solid tumors can differentiate into hematopoietic-like cells, such as macrophages, indicating a reciprocal relationship. Conversely, HSCs recruited into the tumor microenvironment (TME) may be instructed by malignant cells to differentiate into immunosuppressive myeloid cells or other tumor-promoting phenotypes, such as tumor-associated macrophages or myeloid-derived suppressor cells.
- Mechanism: This transformation is driven by genetic mutations in HSCs (leading to leukemia) or by microenvironmental cues (cytokines, chemokines) in the TME that redirect HSC differentiation toward pathological states rather than normal hematopoiesis.[2]
The dark side of stemness – the role of hematopoietic stem cells in development of blood malignancies, 2024
https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2024.1308709/full
Tumor-associated hematopoietic stem and progenitor cells positively linked to glioblastoma progression, 2021
https://www.nature.com/articles/s41467-021-23995-z
Can a bone marrow-derived stem cell differentiate into a cancer tumor cell phenotype?
Yes — but the answer depends on which bone marrow-derived stem cell you mean and what “cancer tumor cell phenotype” means in context. Bone marrow contains several stem cell populations, and their relationship to cancer differs:
Mesenchymal stem cells (MSCs) — the most relevant to your question:
- As tumor-promoting stromal cells (not cancer cells themselves): BM-MSCs are recruited to solid tumors via chemokines (CXCL12/SDF-1α, TGF-β) and differentiate into cancer-associated fibroblasts (CAFs), endothelial-like cells,[1] pericytes, or macrophage-like cells. In gastric cancer models, ~20% of CAFs at the tumor site are derived from recruited BM-MSCs. These are not cancer cells but tumor-supporting stromal cells.[2]
- As cells-of-origin for sarcomas: Transformed MSCs are considered the likely cell-of-origin for several sarcoma subtypes. In long-term culture, human MSCs undergo spontaneous malignant transformation in up to ~46% of cultures, acquiring aneuploidy, elevated telomerase, and the ability to form sarcoma-like tumors in immunodeficient mice.[3]
- Trans-differentiation into multiple tumor types: A landmark 2006 study showed that a single transformed BM-derived cell could self-renew and differentiate into epithelial, neural, muscular, fibroblastic, and endothelial tumor cells in vivo, forming teratomas — suggesting multipotent cancer stem cells can originate from transformed BMDCs.[4]
Key distinction from the HSC answer:
| HSCs | BM-MSCs | |
| Primary cancer link | Leukemias (AML, CLL) | Sarcomas; TME stromal support |
| “Cancer phenotype” | Become malignant hematopoietic cells | Become CAFs (stromal) or undergo sarcomatous transformation |
| Mechanism | Oncogenic mutations at HSC level | Spontaneous transformation, chronic inflammation, or TME reprogramming |
So BM-MSCs can acquire a cancer-associated phenotype (CAF) without being cancer cells, and can also undergo true malignant transformation to become tumor-initiating cells — particularly in sarcoma.
Differentiation and transdifferentiation potentials of cancer stem cells, 2015
https://pmc.ncbi.nlm.nih.gov/articles/PMC4741845/
The Role of Mesenchymal Stem Cells in the Induction of Cancer-Stem Cell Phenotype, 2022
https://pmc.ncbi.nlm.nih.gov/articles/PMC8891610/
Mesenchymal stem cells in tumor development, 2012
https://pmc.ncbi.nlm.nih.gov/articles/PMC3427236/
Multiple Tumor Types May Originate from Bone Marrow-Derived Cells, 2006